Ofatumumab
|
Better Known as: Arzerra
- Marketed By: Genmab & GlaxoSmithKline
- Major Indication: Chronic Lymphocytic Leukemia
- Drug Class: Anti-CD20 Monoclonal Antibody
- Date of FDA Approval (Patent Expiration): 2009 (2023)
- 2009 Sales: $3.1 Billion
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
References